Compare Delta Air Lines, Inc. (DAL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Medpace Holdings Inc — how do they compare? Delta Air Lines, Inc. trades at $82.17 (market cap $54.02B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: Delta Air Lines, Inc. is far larger — about 3.2× Medpace Holdings Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Medpace Holdings Inc for 14 Days on average.
| DAL | MEDP | |
|---|---|---|
Market Cap | $54.02B | $16.82B |
Volume | 9,632,845 | 223,093 |
Sector | Industrials | Health |
52-Week High | $93.66 | $630.19 |
52-Week Low | $55.65 | $393.42 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $69.34B | $16.44B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.14, down 1.0% on the day, amid a bearish technical signal but supported by strong analyst consensus. The stock shows solid fundamentals with a P/E of 13.62, net income margin of 5.78%, and consistent earnings beats in recent quarters, though it missed Q3 2026 estimates. Revenue has grown from $50.6B in 2022 to $63.4B in 2025, while debt-to-asset ratio improved to 17.35%, reflecting stronger financial health. Recent news highlights competitive pressures from rivals and fuel cost concerns, but expansion in European routes offers growth potential.
The outlook for DAL is cautiously optimistic, with a consensus price target of $103.36 implying 26% upside, driven by operational efficiency and travel demand. Key risks include volatile fuel prices, competitive threats from United and American Airlines, and macroeconomic sensitivity. Institutional sentiment remains bullish with 82% buy ratings, but investors should monitor earnings sustainability and cost management amid industry headwinds.
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
